{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:37:15Z","timestamp":1789432635673,"version":"build-2803163510"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Dutch Governmental"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intravenous immunoglobulins are an efficacious treatment for chronic inflammatory demyelinating polyradiculoneuropathy. Biomarkers for disease activity are lacking, making the need for ongoing treatment difficult to assess, leading to potential overtreatment and high health-care costs. Our objective was to determine whether intravenous immunoglobulin withdrawal is non-inferior to continuing intravenous immunoglobulin treatment and to determine how often patients are overtreated.<\/jats:p>\n                  <jats:p>We performed a randomized, double-blind, intravenous immunoglobulin-controlled non-inferiority trial in seven centres in the Netherlands (Trial registration: ISRCTN 13637698; www.isrctn.com\/ISRCTN13637698). Adults with clinically stable chronic inflammatory demyelinating polyradiculoneuropathy using intravenous immunoglobulin maintenance treatment for at least 6 months were included. Patients received either intravenous immunoglobulin withdrawal (placebo) as investigational treatment or continuation of intravenous immunoglobulin treatment (control). The primary outcome was the mean change in logit scores from baseline to 24-week follow-up on the patient-reported Inflammatory Rasch\u2013Overall Disability Scale. The non-inferiority margin was predefined as between-group difference in mean change scores of \u22120.65. Patients who deteriorated could reach a relapse end point according to predefined criteria. Patients with a relapse end point after intravenous immunoglobulin withdrawal entered a restabilization phase. All patients from the withdrawal group who remained stable were included in an open-label extension phase of 52 weeks.<\/jats:p>\n                  <jats:p>We included 60 patients, of whom 29 were randomized to intravenous immunoglobulin withdrawal and 31 to continuation of treatment. The mean age was 58 years (SD 14.7) and 67% was male. The between-group difference in mean change Inflammatory Rasch\u2013Overall Disability Scale scores was \u22120.47 (95% CI \u22121.24 to 0.31), indicating that non-inferiority of intravenous immunoglobulin withdrawal could not be established. In the intravenous immunoglobulin withdrawal group, 41% remained stable for 24 weeks, compared to 58% in the intravenous immunoglobulin continuation group (\u221217%; 95% CI \u221239 to 8). Of the intravenous immunoglobulin withdrawal group, 28% remained stable at the end of the extension phase. Of the patients in the restabilization phase, 94% restabilized within 12 weeks.<\/jats:p>\n                  <jats:p>In conclusion, it remains inconclusive whether intravenous immunoglobulin withdrawal is non-inferior compared to continuing treatment, partly due to larger than expected confidence intervals leading to an underpowered study. Despite these limitations, a considerable proportion of patients could stop treatment and almost all patients who relapsed were restabilized quickly. Unexpectedly, a high proportion of intravenous immunoglobulin-treated patients experienced a relapse end point, emphasizing the need for more objective measures for disease activity in future trials, as the patient-reported outcome measures might not have been able to identify true relapses reliably. Overall, this study suggests that withdrawal attempts are safe and should be performed regularly in clinically stable patients.<\/jats:p>","DOI":"10.1093\/brain\/awac054","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T15:11:45Z","timestamp":1644246705000},"page":"1641-1652","source":"Crossref","is-referenced-by-count":34,"title":["Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy"],"prefix":"10.1093","volume":"145","author":[{"given":"Max E.","family":"Adrichem","sequence":"first","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam , 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-774X","authenticated-orcid":false,"given":"Ilse M.","family":"Lucke","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam , 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander F. J. E.","family":"Vrancken","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Centre , 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Stephan","family":"Goedee","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Centre , 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luuk","family":"Wieske","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam , 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel G. W.","family":"Dijkgraaf","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology, Amsterdam UMC, University of Amsterdam , 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol C.","family":"Voermans","sequence":"additional","affiliation":[{"name":"Department of Neurology, Radboud University Medical Centre , 6525 GA Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolette C.","family":"Notermans","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Medical Centre , 3584 CX Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina G.","family":"Faber","sequence":"additional","affiliation":[{"name":"Department of Neurology, Maastricht Academic Medical Centre , 6229 HX Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo H.","family":"Visser","sequence":"additional","affiliation":[{"name":"Department of Neurology, Elisabeth-Tweesteden Hospital , 5022 GC Tilburg, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Kuitwaard","sequence":"additional","affiliation":[{"name":"Department of Neurology, Albert Schweitzer Hospital , 3318 AT Dordrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter A.","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Erasmus Medical Centre , 3015 GD Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingemar S. J.","family":"Merkies","sequence":"additional","affiliation":[{"name":"Department of Neurology, Radboud University Medical Centre , 6525 GA Nijmegen, The Netherlands"},{"name":"Department of Neurology, Cura\u00e7ao Medical Centre , Willemstad, Curacao, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob J.","family":"de Haan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam , 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo N.","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam , 1105 AZ Amsterdam, The Netherlands"},{"name":"Board of directors, Spaarne Gasthuis , 2035 RC Haarlem, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[{"name":"Department of Neurology, Amsterdam UMC, University of Amsterdam , 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"issue":"3","key":"2022060319043647400_awac054-B1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral nerve society","volume":"17","author":"Van den Bergh","year":"2010","journal-title":"Eur J Neurol"},{"issue":"12","key":"2022060319043647400_awac054-B2","first-page":"CD001797","article-title":"Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy","author":"Eftimov","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2022060319043647400_awac054-B3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1474-4422(17)30378-2","article-title":"Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"van Schaik","year":"2018","journal-title":"Lancet Neurol"},{"issue":"2","key":"2022060319043647400_awac054-B4","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): A randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neurol"},{"issue":"6","key":"2022060319043647400_awac054-B5","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1474-4422(12)70093-5","article-title":"Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: A randomised controlled trial","volume":"11","author":"Nobile-Orazio","year":"2012","journal-title":"Lancet Neurol"},{"issue":"8","key":"2022060319043647400_awac054-B6","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(18)30202-3","article-title":"Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial):A double-blind, multicentre, randomised controlled trial","volume":"17","author":"Hughes","year":"2018","journal-title":"Lancet Neurol"},{"key":"2022060319043647400_awac054-B7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jns.2018.11.031","article-title":"Current practice patterns in CIDP: A cross-sectional survey of neurologists in the United States","volume":"397","author":"Gelinas","year":"2019","journal-title":"J Neurol Sci"},{"issue":"1","key":"2022060319043647400_awac054-B8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"issue":"4","key":"2022060319043647400_awac054-B9","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1212\/WNL.0b013e318208824b","article-title":"Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies","volume":"76","author":"van Nes","year":"2011","journal-title":"Neurology"},{"issue":"4","key":"2022060319043647400_awac054-B10","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1212\/WNL.54.4.943","article-title":"Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies","volume":"54","author":"Merkies","year":"2000","journal-title":"Neurology"},{"issue":"4","key":"2022060319043647400_awac054-B11","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1529-8027.2009.00238.x","article-title":"Improving fatigue assessment in immune-mediated neuropathies: The modified Rasch-built fatigue severity scale","volume":"14","author":"van Nes","year":"2009","journal-title":"J Peripher Nerv Syst"},{"key":"2022060319043647400_awac054-B12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1477-7525-3-83","article-title":"The Academic Medical Center Linear Disability Score (ALDS) item bank: Item response theory analysis in a mixed patient population","volume":"3","author":"Holman","year":"2005","journal-title":"Health Qual Life Outcomes"},{"issue":"3","key":"2022060319043647400_awac054-B13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","article-title":"The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs","volume":"31","author":"McHorney","year":"1993","journal-title":"Med Care"},{"issue":"23","key":"2022060319043647400_awac054-B14","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1212\/WNL.0000000000001044","article-title":"Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness","volume":"83","author":"Draak","year":"2014","journal-title":"Neurology"},{"key":"2022060319043647400_awac054-B15","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1214\/aoms\/1177704172","article-title":"Estimates of location based on rank tests","volume":"34","author":"Hodges","year":"1963","journal-title":"Ann Math Statist"},{"issue":"7","key":"2022060319043647400_awac054-B16","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jnnp-2013-307515","article-title":"Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP","volume":"86","author":"Nobile-Orazio","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2022060319043647400_awac054-B17","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/jns.12303","article-title":"Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy and Treatment with Hizentra study","volume":"24","author":"Mielke","year":"2019","journal-title":"J Peripher Nerv Syst"},{"issue":"7","key":"2022060319043647400_awac054-B18","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/ene.13025","article-title":"Correlation of the patient\u2019s reported outcome Inflammatory-RODS with an objective metric in immune-mediated neuropathies","volume":"23","author":"Draak","year":"2016","journal-title":"Eur J Neurol"},{"issue":"1\u20132","key":"2022060319043647400_awac054-B19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10555-019-09800-w","article-title":"It is not just the drugs that matter: The nocebo effect","volume":"38","author":"Wojtukiewicz","year":"2019","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"2022060319043647400_awac054-B20","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/jns.12402","article-title":"Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review","volume":"25","author":"Lewis","year":"2020","journal-title":"J Peripher Nerv Syst"},{"issue":"5","key":"2022060319043647400_awac054-B21","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1468-1331.2012.03851.x","article-title":"Vigorimeter grip strength in CIDP: A responsive tool that rapidly measures the effect of IVIG\u2014the ICE study","volume":"20","author":"Vanhoutte","year":"2013","journal-title":"Eur J Neurol"},{"issue":"6","key":"2022060319043647400_awac054-B22","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/EDE.0000000000000160","article-title":"The parametric g-formula for time-to-event data: Intuition and a worked example","volume":"25","author":"Keil","year":"2014","journal-title":"Epidemiology"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awac054\/43537369\/awac054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awac054\/43948432\/awac054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awac054\/43948432\/awac054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T15:05:45Z","timestamp":1654268745000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/145\/5\/1641\/6525350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,2,9]]},"published-print":{"date-parts":[[2022,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awac054","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741614482.793593570","asserted-by":"object"}]},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,2,9]]}}}